<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01927068</url>
  </required_header>
  <id_info>
    <org_study_id>CP-1005</org_study_id>
    <secondary_id>CP-1005</secondary_id>
    <nct_id>NCT01927068</nct_id>
  </id_info>
  <brief_title>Global Study of a Drug-coated Balloon to Treat Obstructive SFA and/or Popliteal Lesions</brief_title>
  <acronym>ILLUMENATE</acronym>
  <official_title>ILLUMENATE GLOBAL and ISR: Prospective, Single-Arm, Global Multi-Center Study to Evaluate Treatment of Obstructive Superficial Femoral Artery (SFA) and/or Popliteal Lesions With a Novel Paclitaxel-Coated Percutaneous Angioplasty (PTA) Balloon and in In-Stent Restenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectranetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectranetics Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cohort 1: Single-Arm, multicenter study to continue to assess the safety and performance of&#xD;
      the Cardiovascular Ingenuity (CVI) Paclitaxel-Coated PTA Balloon Catheter in the treatment of&#xD;
      de novo or restenotic lesions in the superficial femoral and/or popliteal arteries Cohort 2:&#xD;
      To evaluate this patient population for treatment of in-stent restenotic lesions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cohort 1:&#xD;
&#xD;
      The purpose of this single arm study is to continue to assess safety and performance of the&#xD;
      CVI Paclitaxel-Coated PTA Balloon Catheter in the treatment of de novo or restenotic lesions&#xD;
      in the superficial femoral (SFA) and/or popliteal arteries.&#xD;
&#xD;
      Cohort 2:&#xD;
&#xD;
      A second cohort is being added to evaluate this patient population for treatment of in-stent&#xD;
      restenotic lesions.&#xD;
&#xD;
      Cohort 1:&#xD;
&#xD;
      Prospective, multi-center, single-arm study.&#xD;
&#xD;
      Cohort 2:&#xD;
&#xD;
      Prospective, multi-center, single-arm study compared to a historical control patients.&#xD;
&#xD;
      Cohort 1:&#xD;
&#xD;
      Follow-up assessments will occur at discharge, 1 month, 6 months, 12 months, 24 months,36&#xD;
      months, 48 months, and 60 months following the study procedure.&#xD;
&#xD;
      Cohort 2:&#xD;
&#xD;
      Follow-up assessments will occur at discharge, 1 month, 6 months, 12 months, 24 months and 36&#xD;
      months following the study procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Actual">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>Through 30 days post-procedure.</time_frame>
    <description>Freedom from device and procedure-related death through 30 days post-procedure and freedom from target limb major amputation and clinically-driven target lesion revascularization (TLR) through 12 months post-procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint</measure>
    <time_frame>12 months post-procedure.</time_frame>
    <description>Primary patency at 12 months post-procedure. Primary patency is defined as the absence of target lesion restenosis per duplex ultrasound (peak systolic velocity ratio (PSVR) ≤ 2.5) and freedom from clinically-driven target lesion revascularization.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Global Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects to be treated with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTX PTA) Balloon Catheter in Cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Global ISR Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For Cohort 2, the same device was commercially available, and subjects were to be treated with the CE Marked, renamed device Stellarex 0.035&quot; OTW drug-coated angioplasty balloon (Stellarex 035 DCB)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CVI Paclitaxel-Coated PTA Balloon Catheter</intervention_name>
    <description>Percutaneous Transluminal Angioplasty will be completed using a 2.0 micrograms per square millimeter. Paclitaxel-Coated Balloon. Balloon will be inflated to a size appropriate for the target vessel, as determined by the physician. Total balloon inflation time is determined by the physician, but no less than one minute.</description>
    <arm_group_label>Global Cohort 1</arm_group_label>
    <arm_group_label>Global ISR Cohort 2</arm_group_label>
    <other_name>Stellarex 0.035&quot; Over-the-Wire (OTW) drug-coated angioplasty balloon (Stellarex DCB)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Cohort 1: General Inclusion Criteria:&#xD;
&#xD;
          1. Has symptomatic leg ischemia, requiring treatment of the SFA and/or popliteal artery.&#xD;
&#xD;
          2. Has a Rutherford Clinical Category of 2 - 4. Note: Rutherford Clinical Category 2&#xD;
             subjects should be entered into the study if conservative treatment has been&#xD;
             unsuccessful.&#xD;
&#xD;
          3. Is ≥18 years old.&#xD;
&#xD;
          4. Has life expectancy &gt;1 year.&#xD;
&#xD;
          5. Is able and willing to provide written informed consent prior to study specific&#xD;
             procedures.&#xD;
&#xD;
          6. Is willing and capable of complying with the required follow-up visits, testing&#xD;
             schedule and medication regimen.&#xD;
&#xD;
        Cohort 1: Angiographic Inclusion Criteria:&#xD;
&#xD;
          1. Has evidence at the target lesion(s) of clinically and hemodynamically significant de&#xD;
             novo stenosis or restenosis, or occlusion, in the SFA (1 cm distal to the ostium of&#xD;
             the profunda) and/or popliteal artery (proximal to the popliteal trifurcation),&#xD;
             confirmed by angiography.&#xD;
&#xD;
          2. Has target limb with at least one patent (&lt;50% stenosis) tibio-peroneal run-off vessel&#xD;
             to the foot confirmed by baseline angiography or magnetic resonance angiography (MRA)&#xD;
             or computed tomography angiography (CTA). Note: Treatment of outflow disease is NOT&#xD;
             permitted.&#xD;
&#xD;
          3. Has 1 or 2 target lesion(s) with a cumulative lesion(s) length of no more than 20 cm.&#xD;
             Note: A maximum of two (2) lesions can be treated if the cumulative total lesion&#xD;
             length (i.e. the combined length of both lesions) is less than or equal to 20cm.&#xD;
&#xD;
          4. Has target lesion(s) located &gt;2 cm from any stent if the target vessel was previously&#xD;
             stented.&#xD;
&#xD;
          5. Has a reference vessel diameter of 4 - 6 mm by visual estimate.&#xD;
&#xD;
          6. Has a successful exchangeable guidewire crossing of the lesion(s).&#xD;
&#xD;
        Cohort 1: General Exclusion Criteria:&#xD;
&#xD;
          1. A female who is pregnant, of childbearing potential not taking adequate contraceptive&#xD;
             measures, or nursing; or a male intending to father children during the study.&#xD;
&#xD;
          2. Has significant gastrointestinal bleeding or any coagulopathy that would&#xD;
             contraindicate the use of anti-platelet therapy&#xD;
&#xD;
          3. Has known intolerance to study medications, paclitaxel or contrast agents that in the&#xD;
             opinion of the investigator cannot be adequately pre-treated.&#xD;
&#xD;
          4. Is currently participating in another investigational device or drug study that would&#xD;
             interfere with study endpoints.&#xD;
&#xD;
          5. Has history of hemorrhagic stroke within 3 months.&#xD;
&#xD;
          6. Has surgical or endovascular procedure of the target limb within 14 days prior to the&#xD;
             index procedure.&#xD;
&#xD;
          7. Has any planned surgical intervention (requiring hospitalization) or endovascular&#xD;
             procedure within 30 days after the index procedure.&#xD;
&#xD;
          8. Has had a previous peripheral bypass affecting the target limb.&#xD;
&#xD;
          9. Has unstable angina pectoris, myocardial infarction, liver failure, renal failure or&#xD;
             chronic kidney disease (dialysis dependent, or serum creatinine ≥2.5 mg/dL) within 30&#xD;
             days of the index procedure.&#xD;
&#xD;
        Cohort 1: Angiographic Exclusion Criteria:&#xD;
&#xD;
          1. Has significant stenosis (≥50%) or occlusion of inflow tract that is not successfully&#xD;
             revascularized (&lt;30% residual stenosis without death or major vascular complication)&#xD;
             prior to treatment of the target lesion(s). Only treatment of target lesion(s) is&#xD;
             acceptable after successful treatment of inflow iliac artery lesion(s).&#xD;
&#xD;
          2. Has an acute or sub-acute intraluminal thrombus within the target vessel.&#xD;
&#xD;
          3. Has in-stent restenosis or restenosis of the target lesion following previous&#xD;
             treatment with a drug-coated balloon.&#xD;
&#xD;
          4. Has an aneurysm (at least twice the reference vessel diameter) located in the target&#xD;
             vessel, abdominal aorta, iliac, or popliteal arteries.&#xD;
&#xD;
          5. Has perforation, dissection or other injury of the access or target vessel requiring&#xD;
             stenting or surgical intervention prior to enrollment.&#xD;
&#xD;
          6. Has no normal arterial segment proximal to the target lesion in which duplex&#xD;
             ultrasound velocity ratios can be measured.&#xD;
&#xD;
          7. Requires use of adjunctive therapies (i.e., laser, atherectomy, cryoplasty,&#xD;
             scoring/cutting balloons, brachytherapy).&#xD;
&#xD;
          8. Has severe calcification that precludes adequate PTA treatment.&#xD;
&#xD;
        Cohort 2: General Inclusion Criteria:&#xD;
&#xD;
          1. Has symptomatic leg ischemia, requiring treatment of the SFA and/or popliteal artery.&#xD;
&#xD;
          2. Has a Rutherford Clinical Category of 2 - 4. Note: Rutherford Clinical Category 2&#xD;
             subjects should be entered into the study if conservative treatment has been&#xD;
             unsuccessful.&#xD;
&#xD;
          3. Is between 18-85 years old.&#xD;
&#xD;
          4. Has life expectancy &gt;1 year.&#xD;
&#xD;
          5. Is able and willing to provide written informed consent prior to study specific&#xD;
             procedures.&#xD;
&#xD;
          6. Is willing and capable of complying with the required follow-up visits, testing&#xD;
             schedule and medication regimen.&#xD;
&#xD;
          7. History of previous femoropopliteal nitinol stenting which is suspect for in-stent&#xD;
             restenosis.&#xD;
&#xD;
          8. The patient has a resting ankle-brachial index (ABI) &lt;0.9 or an abnormal exercise ABI&#xD;
             (&lt;0.9) if resting ABI is normal. Patient with incompressible arteries (ABI&gt;1.2) must&#xD;
             have a toe-brachial index (TBI) &lt;0.7 in target limb.&#xD;
&#xD;
        Cohort 2: Angiographic Inclusion Criteria:&#xD;
&#xD;
          1. Has angiographic evidence of significant restenosis (≥50% by visual estimate) within a&#xD;
             previously deployed femoropopliteal bare nitinol stent(s) including ISR Class I, II or&#xD;
             III.&#xD;
&#xD;
          2. Has target limb with at least one patent (&lt;50% stenosis) tibio-peroneal run-off vessel&#xD;
             to the foot confirmed by baseline angiography or magnetic resonance angiography (MRA)&#xD;
             or computed tomography angiography (CTA). Note: Treatment of outflow disease is NOT&#xD;
             permitted.&#xD;
&#xD;
          3. Total target treatment length of in-stent restenosis must be ≥4.0 cm in length and may&#xD;
             include a single lesion or a multifocal lesion within the femoropopliteal segment&#xD;
             (This includes the proximal, mid, and/or distal SFA and PI, P2 and/or P3 segment of&#xD;
             the popliteal artery). Edge restenosis may be treated provided the lesion extends no&#xD;
             more than 3 cm outside the margin of the stent (proximal and/or distal margin).&#xD;
&#xD;
          4. Has target lesion(s) located &gt;2 cm from any stent if the target vessel was previously&#xD;
             stented.&#xD;
&#xD;
          5. Has a reference vessel diameter of 4 - 6 mm by visual estimate.&#xD;
&#xD;
          6. Has a successful exchangeable guidewire crossing of the lesion(s).&#xD;
&#xD;
        Cohort 2: General Exclusion Criteria:&#xD;
&#xD;
          1. A female who is pregnant, of childbearing potential not taking adequate contraceptive&#xD;
             measures, or nursing; or a male intending to father children during the study.&#xD;
&#xD;
          2. Has significant gastrointestinal bleeding or any coagulopathy that would&#xD;
             contraindicate the use of anti-platelet therapy.&#xD;
&#xD;
          3. Has known intolerance to study medications, paclitaxel or contrast agents that in the&#xD;
             opinion of the investigator cannot be adequately pre-treated.&#xD;
&#xD;
          4. Is currently participating in another investigational device or drug study that would&#xD;
             interfere with study endpoints.&#xD;
&#xD;
          5. Has history of hemorrhagic stroke within 3 months including those within &lt;60 days with&#xD;
             an unresolved walking impairment.&#xD;
&#xD;
          6. Has surgical or endovascular procedure of the target limb within 3 months prior to the&#xD;
             index procedure.&#xD;
&#xD;
          7. Has any planned surgical intervention (requiring hospitalization) or endovascular&#xD;
             procedure within 30 days after the index procedure.&#xD;
&#xD;
          8. Has had a previous peripheral bypass affecting the target limb.&#xD;
&#xD;
          9. Has unstable angina pectoris, myocardial infarction within 60 days, liver failure,&#xD;
             renal failure or chronic kidney disease (dialysis dependent, or serum creatinine ≥2.5&#xD;
             mg/dL) within 30 days of the index procedure.&#xD;
&#xD;
         10. History of previous femoropopliteal stenting in the target lesion with drug eluting&#xD;
             stents or covered stents (endografts).&#xD;
&#xD;
        Cohort 2: Angiographic Exclusion Criteria:&#xD;
&#xD;
          1. Ipsilateral and/or contralateral iliac (or common femoral) artery stenosis&#xD;
&#xD;
             ≥50% diameter stenosis (DS) that is not successfully treated prior to index procedure&#xD;
             (e.g. where a perforation occurred requiring a covered stent) or with final residual&#xD;
             stenosis ≥ 30% documented by angiography.&#xD;
&#xD;
          2. Identification of any lesion of the native vessel (excludes ISR) above the target&#xD;
             stent in the femoropopliteal segment &gt;50% that is not successfully treated prior to&#xD;
             index procedure (e.g. complication requiring additional treatment) or with final&#xD;
             residual stenosis &gt;30% documented by angiography. Drug eluting stent (DES) and drug&#xD;
             coated balloon (DCB) will not be allowed. The lesion length must be treatable with a&#xD;
             single stent (if required). The lesion must not be contiguous with the target lesion;&#xD;
             at least 2 cm of normal appearing vessel between the lesion and target lesion/ target&#xD;
             stent or between deployed stent (if required) and the target lesion/ target stent.&#xD;
&#xD;
          3. Has an acute or sub-acute intraluminal thrombus within the target vessel.&#xD;
&#xD;
          4. Has an aneurysm (at least twice the reference vessel diameter) located in the target&#xD;
             vessel, abdominal aorta, iliac, or popliteal arteries.&#xD;
&#xD;
          5. Has perforation, dissection or other injury of the access or target vessel requiring&#xD;
             stenting or surgical intervention prior to enrollment.&#xD;
&#xD;
          6. Has no normal arterial segment proximal to the target lesion in which duplex&#xD;
             ultrasound velocity ratios can be measured.&#xD;
&#xD;
          7. Requires use of adjunctive therapies (i.e., laser, atherectomy, cryoplasty,&#xD;
             scoring/cutting balloons, brachytherapy).&#xD;
&#xD;
          8. Grade 4 or 5 stent fracture affecting target stent or proximal to the target stent, or&#xD;
             where evidence of stent protrusion into the lumen is noted on angiography in 2&#xD;
             orthogonal views.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Zeller, MBChB, FRANZCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herz-Zentrum Bad Krozingen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Holden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Auckland Hospital, New Zealand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yann Goueffic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Nord Laennec, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Wesley St. Andrew Research Institute Ltd.</name>
      <address>
        <city>Auchenflower</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre at Dandenong Campus</name>
      <address>
        <city>Dandenong</city>
        <zip>3175</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Graz - Univ. Klinik für Innere Medizin</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middelheim Hospital</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda Hospital</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Blasius</name>
      <address>
        <city>Dendermonde</city>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZOL Campus Sint Jan</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionaal Ziekenhuis Heilig Hart Tienen, Campus Mariëndal - MCT, Vascular Surgery Department</name>
      <address>
        <city>Tienen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand, Hôpital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon, Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Ia Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes, Hôpital Nord Laennec</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes, Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitats-Herzzentrum Freiburg - Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jüdisches Krankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>3347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik III</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Immenstadt, Herz-und Gefässzentrum Oberallgäu-Kempten</name>
      <address>
        <city>Immenstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Klinikum Karlsbad-Langensteinbach</name>
      <address>
        <city>Langensteinbach</city>
        <zip>76307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Leipzig Medical Center</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RoMed Klinikum Rosenheim</name>
      <address>
        <city>Rosenheim</city>
        <zip>83022</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik, Abteilung Für Diagnostische und Inverventionelle Radiologie</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti - SOD</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Villa Maria Eleonora Hospital</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Chirurgia Vascolare ed Endovascolare</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>2015</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Atencio Integral Hospital Dos de Maig</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quirón de Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Academic and Healthcare NHS Trust, St. Mary's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Division of Surgery and Interventional Science</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 25, 2013</study_first_submitted>
  <study_first_submitted_qc>August 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2013</study_first_posted>
  <last_update_submitted>October 14, 2020</last_update_submitted>
  <last_update_submitted_qc>October 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 14, 2021</submitted>
    <returned>November 12, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

